The advent of highly active antiretroviral therapy (HAART) has transformed the clinical outcomes for people with HIV. Antiviral therapies deliver suppression of viral replication with immune reconstitution, an attendant decrease in opportunistic infections, and improvements in life expectancy. 1 Nonetheless, the rates of intercurrent malignancies remain elevated, with hematological malignancies prominent. 2 Optimal management of malignancies in patients with HIV remains incompletely defined. Therapeutic options were historically limited by immunodeficiency, and clinical outcomes were correspondingly poor. Recently, progress has enabled evaluation of intensive therapies. There is now evidence regarding the safety and efficacy of myelosuppressive chemotherapy, and of a place emerging for auto-SCT. 3 However, although studies have described solid organ transplantation, there are few data regarding allo-SCT. [3] [4] [5] We discuss our experience with allo-SCT in three patients with HIV and hematological malignancies.
Case 1
A 38-year-old man had a 12-year history of HIV, previously complicated by the AIDS-defining illness (ADI) Pneumocystis jiroveci pneumonia with a CD4 nadir of 7 cells/ml. AML was diagnosed 8 years previously with CR achieved following the standard chemotherapy, with subsequent relapse managed with reinduction chemotherapy and auto-SCT. After a 4-year interval, therapy-related myelodysplasia (RAEB-1) developed.
He received an HLA-identical peripheral blood (PB) SCT from an unrelated volunteer donor conditioned with CY 120 mg/kg and TBI 13.2 Gy in six fractions, with GVHD and infection prophylaxis with cyclosporin 3 mg/ kg/day, ganciclovir, sulfamethoxazole/trimethoprim and itraconazole. HIV viral load (VL) was undetectable, with a CD4 count of 578 cells/ml. Before transplantation, antiretrovirals were altered to tenofovir, stavudine and lamivudine to minimize drug interactions and avoid additional myelosuppression.
Transplantation was complicated by BK virus-associated hemorrhagic cystitis and prolonged neutropenia with Escherichia coli sepsis, the latter responsive to meropenem. Antiretrovirals were considered to be contributory to persistent neutropenia and were withdrawn from day 30. He had no clinical GVHD. HIV VL remained undetectable, with the CD4 falling to 31 cells/ml ( Figure 1 ). Engraftment occurred on day 48, BM aspirate and trephine (BMAT) confirmed remission.
There were no late infective complications. Antiretroviral therapy was reintroduced after 12 months in response to a rising HIV VL, with no recurrence of myelosuppression. The patient remained in remission 22 months after transplant, with HIV VL of 150 copies/ml and CD4 of 181 cells/ml. He subsequently developed post transplant glomerulopathy, declined renal replacement therapy, and succumbed to complications of renal failure 24 months after transplant.
Case 2
A 41-year-old man had a 12-year history of HIV without ADIs, and multiply relapsed AML with t(9;11) diagnosed 4 years previously. HIV VL was undetectable and the CD4 count was 275 cells/ml; his CD4 nadir had been 10 cells/ml.
He received an HLA-identical sibling PBSCT in CR3 with conditioning and prophylaxis as in case 1, plus additional antimicrobial prophylaxis with entecavir for chronic hepatitis B, azithromycin for Mycobacterium avium complex and ciprofloxacin for a recent rhodococcus pulmonary infection. He had HIV drug resistance across multiple classes, and was switched to his fifth antiretroviral regimen of tenofovir, emtricitabine and fosamprenavir/ ritonavir before transplantation.
Transplantation was complicated by culture-negative neutropenic sepsis responsive to piperacillin/tazobactam, pericarditis of undefined etiology and grade 2 cutaneous GVHD. HIV VL remained undetectable, with the CD4 falling to 148 cells/ml (Figure 1 ), antiretrovirals were continued throughout. Engraftment occurred on day 21, BMAT confirmed remission.
The patient remained well with no further complications until day 67, when he developed multidrug-resistant pseudomonal sepsis with multiorgan failure and succumbed on day 78 despite anti-infective therapy.
Case 3
A 24-year-old man had a 2-year history of HIV with no ADIs, and T-cell ALL in CR2. HIV VL was undetectable and the CD4 count was 204 cells/ml.
He received an HLA-identical sibling PBSCT conditioned with etoposide 60 mg/kg and TBI 13.2 Gy in six fractions, with anti-microbial prophylaxis as in case 1 plus palifermin. Antiretrovirals were altered to tenofovir, emtricatabine and fosamprenavir/ritonavir. Transplantation was complicated by dental infection treated with piperacillin/tazobactam and grade 2 cutaneous GVHD, responsive to corticosteroid therapy. Antiretrovirals were continued, with HIV VL remaining undetectable and CD4 4200 cells/ml (Figure 1 ). Engraftment occurred on day 25, BMAT confirmed remission.
The patient remained well with no further complications, and an undetectable HIV VL and CD4 counts 4200 cells/ ml until his disease relapsed on day 101. After declining further therapy, he succumbed on day 105.
Conclusion
The occurrence of hematological malignancies in patients with HIV creates an unmet clinical need, where conventional therapies are unsuitable or ineffective. Despite this, there has been little exploration of the potential utility of allo-SCT. Of the few reported cases, many predate HAART, meaning that outcomes should be interpreted with caution. 3, 5 Promising outcomes with non-malignant disease, and others using reduced-intensity conditioning have recently been reported. [6] [7] [8] [9] Of particular interest is a recent case report describing allogeneic transplantation as dual therapy of AML and HIV. 10 In the reported case, a patient with newly diagnosed AML with normal cytogenetics and a 10-year history of HIV on HAART with no ADIs received as first-line therapy an allogeneic transplant from a CCR5 delta32/ delta32 HLA-matched unrelated donor. The CCR5 delta32/delta32 mutation inactivates a major point of HIV entry into host cells, conferring a high degree of resistance to HIV infection. He achieved engraftment with consequent switch in CCR5 genotype to the delta32/delta32 mutated form, and showed no reactivation of HIV viral activity in 20 months after transplantation despite withdrawal of HAART. His AML remained in remission. Such an approach, although very preliminary, might prove promising in patients with HIV and other indications for allogeneic transplantation.
Each of the patients in this small series had good virological control and immune parameters. Two had prolonged HIV infection and one antiretroviral drug resistance across multiple classes. Each had undergone multiple courses of chemotherapy, with immune and infective consequences including one invasive fungal infection. Nonetheless, complications were not worse than would be expected in similar heavily pre-treated non-HIV patients. HIV control was maintained after conditioning. There was one septic death in remission, and one early relapse, whereas the remaining patient achieved sustained remission.
We conclude that allo-SCT with standard-intensity conditioning may be a feasible therapeutic modality for high-grade hematological malignancies in patients with HIV, and warrants systematic investigation. Careful patient selection, optimization of HIV control with regimens chosen to minimize drug interactions and toxicity, and preventive management of early and late infection are critical to optimal patient outcomes.
